Genset Corporation
{{Infobox company
| name = Genset
| industry = biotechnology
| successor = Serono
| founded = 1989
| hq_location = Paris, France
}}
Genset, a biotechnology company, was established in 1989 in Paris, France with Pascal Brandys as its first president.Genset: 1989 [http://www.hbs.edu/faculty/Pages/item.aspx?num=8025 Harvard Business School Case Study] Paul A. Gompers, Amy L. Burroughs
The company was listed on the NASDAQ and the Paris Bourse.{{Cite web |title=Genset sets tone for global biotechnology financing |url=https://www.nature.com/articles/nbt0796-810.pdf}}
History
Genset was listed on the NASDAQ and the Paris Bourse (now NYSE Euronext) in 1996.Genset Initial Public Offering [http://www.hbs.edu/faculty/Pages/item.aspx?num=7918 Harvard Business School Case Study] Paul A. Gompers, Jeffrey Anapolsky Genset rapidly became the European flagship company in the field of genomics and became the second-largest biotechnology company in Europe in 1999. At that time, the company reported identifiable assets of EUR 80.9 million and had subsidiaries in the United States, Japan, Singapore, and Australia. Genset was a pioneer in private human genome research.Capitalizing on the genome
[http://www.nature.com/ng/wilma/v13n1.867861436.html Nature Genetics 13, 1-1 (1996)] Editorial In 1994, Genset started the first large scale program to analyze the regulatory sequences of the human genome and in 1997 also initiated the construction of a map of single nucleotide polymorphisms as a tool to accelerate the discovery of genes associated with diseases.Drug firms discuss linking up to pursue disease-causing genes
[http://www.grain.org/bio-ipr/?id=208 The Wall Street Journal (4 March 1999)] Robert Langreth, Michael Waldhoz and Stephen D. Moore
Decoding the literature on genetic variation [http://www.nature.com/nbt/journal/v21/n1/full/nbt0103-21.html Nature Biotechnology 21, 21-29 (2003)] Roger Coronini The company also created the business model of pharmacogenomics and started the first pharmacogenomics research program in the world in collaboration with Abbott Laboratories in 1997.Pharmacogenomics
[http://www.nature.com/nbt/journal/v18/n10s/full/nbt1000_IT40.html Nature Biotechnology 18, 40-42 (2000)] Technologies
After 2000 Genset changed its strategy to focus on drug development, leading to the departure of its president and other founders.{{Citation needed|date=September 2021}} The strategy shift proved unsuccessful and Genset was acquired by Serono of Switzerland in 2002, now part of Merck Serono as Merck launched a takeover bid for Serono in 2006.{{Cite web |date=2006-09-22 |title=Merck s'empare du suisse Serono pour 10,6 milliards d'euros |url=https://www.lesechos.fr/2006/09/merck-sempare-du-suisse-serono-pour-106-milliards-deuros-592352 |access-date=2022-08-20 |website=Les Echos |language=fr}}
References
Category:Biotechnology companies of France
Category:Pharmaceutical companies of France
Category:Pharmaceutical companies established in 1989
Category:Companies listed on the Nasdaq
Category:Pharmaceutical companies disestablished in 2002
Category:Biotechnology companies established in 1989
Category:Biotechnology companies disestablished in 2002
Category:Companies based in Paris